- June (1)
- May (3)
- April (3)
- March (3)
- February (3)
- January (3)
- December (3)
- November (3)
- October (3)
- September (3)
- August (3)
- July (3)
- June (2)
- May (3)
- April (3)
- March (3)
- February (3)
- January (3)
- December (3)
- November (3)
- October (3)
- September (3)
- August (3)
- July (3)
- June (2)
- May (3)
- April (3)
- March (3)
- February (3)
- January (3)
- December (3)
- November (3)
- October (3)
- August (2)
- July (3)
- June (3)
- May (2)
- October (9)
- September (14)
- August (11)
- July (8)
Pages
About Me
- Dan Knottingham
- My Dad used to make up an area outside complete with backyard baseball batting cages, basketball hoop and everything else that could fit. When I was young I dreamed of going to the NBA. Now, I am happy to coach Little League and Steve Nash Minor Basketball!
Andrew Bynum’s Return Likely Delayed?
By Stephen Brotherston
The Philadelphia 76ers knew about Andrew Bynum’s history of knee problems when they acquired the 24-year-old center this summer and it doesn’t appear to have come as much of a surprise that the big man was going to require treatments prior to the start of the season. However, the plan to inject both of Bynum’s knees with Synvisc-One on Monday, October 22 could delay Bynum’s return to the lineup, or even the practice court, a lot longer than team officials are letting on.
According to the company website, Synvisc-One is designed to treat Osteoarthritis, a common form of arthritis pain in the knee. Pain and stiffness is caused by the cartilage protecting the ends of the bones deteriorating and the joint fluid losing its shock-absorbing qualities. Synvisc-One supplements a person’s own joint fluid and can provide up to six months of relief.
However, Synvisc-One takes four weeks after the injection before most patients experience pain relief, there can be side effects such as swelling or fluid buildup and 29 percent of patients do not experience pain relief as a result of the procedure.
Click Here For More
Beal Adjusting to NBA Without Wall
By Alex Raskin
It wasn’t that the Washington Wizards needed more depth in the backcourt. If nothing else, the team already had lightening-fast point guard John Wall
View the Original article
The New Orleans Hornets finished last season 21-45 in the franchise’s first campaign since 2006 without All-Star point guard Chris Paul. With Paul serving as the team’s floor general for six seasons, the Hornets were a perennial threat to reach the playoffs. Now, New Orleans will enter the 2012-13 campaign as one of the youngest teams in the league, still reeling from the loss of Paul and in the midst of a lengthy rebuilding project.
There are three roads to improvement for NBA teams looking to reverse their respective fortunes on the court. The annual draft, trade market and free agency are those paths.
Over the past year, the Hornets believe they have made the right moves in each of those three paths by acquiring high scoring guard Eric Gordon in the Paul trade, selecting former University of Kentucky standout Anthony Davis with the No. 1 overall pick in the draft and signing 2012 Most Improved Player award winner Ryan Anderson to a four-year, $34 million deal in free agency this past summer.
Anderson has developed into one of the league’s premier shooting big men, but has struggled with his shot mightily during the preseason slate as he tries to carve out his niche with a new franchise. The veteran readily admits the transition has been somewhat of a struggle during the early going.
View the Original article
The New York Knicks added a lot of talent over the past two seasons with mixed results. While there was no doubt the team improved, they failed to live up to the very high expectations set by this basketball savvy market, management and themselves. Now, there is a new recipe for success in New York. Experience, and lots of it, will be this team’s calling card. This season, they will be led by three point guards who have a combined 42 years of professional basketball experience between them in Raymond Felton, Jason Kidd and Pablo Prigioni.
View the Original article